In Vitro Evaluation of Ferutinin Rich-Ferula communis L., ssp. glauca, Root Extract on Doxorubicin-Induced Cardiotoxicity: Antioxidant Properties and Cell Cycle Modulation

the clinical use of anthracycline doxorubicin as an antineoplastic drug in cancer therapy is limited by cardiotoxic effects that can lead to congestive heart failure. recent studies have shown several promising activities of different species of the genus Ferula belonging to the apiaceae family. ferula communis is the main source of ferutinin-a bioactive compound isolated from many species of Ferula-studied both in vitro and in vivo because of their different effects, such as estrogenic, antioxidant, anti-inflammatory, and also antiproliferative and cytotoxic activity, performed in a dose-dependent and cell-dependent way. However, the potential protective role of ferutinin in myocardium impairment, caused by chemotherapeutic drugs, still represents an unexplored field. the aim of this study was to test the effects of ferutinin rich-Ferula communis L. root extract (FcFE) at different concentrations on H9C2 cells. moreover, we evaluated its antioxidant properties in cardiomyocytes in order to explore new potential therapeutic activities never examined before in other experimental works. FcFE, at a concentration of 0.25 mu M, in the H9C2 line, significantly reduced the ROS production induced by H2O2 (50 mu M and 250 mu M) and traced the cell mortality of the H9C2 co-treated with ferutinin 0.25 mu M and doxorubicin (0.5 mu M and 1 mu M) to control levels. these results showed that FcFE could protect against doxorubicin-induced cardiotoxicity. further molecular characterization of this natural compound may open the way for testing FcFE at low concentrations in vivo and in clinical studies as an adjuvant in cancer therapy in association with anthracyclines to prevent side effects on heart cells.